Advanced Spatial Quinomics Study Reveals Novel Insights into the Therapeutic Impact of BPM31510, Being Studied as a Potential Treatment for Primary CoQ10 Deficiency and Other Mitochondrial Diseases
BOSTON, MASS., April 25, 2025 – BPGbio, Inc., a leading biology-first, AI-powered clinical-stage biopharma company focused on mitochondrial biology and protein homeostasis, today announced a poster presentation at the inaugural Mitochondrial Transplantation and Next Generation Therapeutics Conference, taking place April 27–29, 2025, in Long Island, N.Y. The presentation will feature novel insights into the pharmacodynamics and tissue distribution of BPM31510, providing valuable biological evidence that it effectively delivers CoQ10 to critically important tissues and tissue regions, including the cerebellum, and restores CoQ10 levels in a genetic model of primary CoQ10 deficiency.
Using cutting-edge spatial quinomics techniques, BPGbio researchers show that BPM31510 significantly increased CoQ10 levels across multiple tissues—including the brain, kidney, muscle, and heart—in Coq4 KI/KI mice (a mouse model of CoQ deficiency) in collaboration with Dr. Catarina Quinzii of Columbia University. Notably, BPM31510 achieved targeted delivery to the cerebellum, a region of the brain whose dysfunction is associated with ataxia, a hallmark symptom of mitochondrial disorders.
Primary CoQ10 deficiency and other mitochondrial diseases are often treated with oral CoQ10 supplements, which have poor bioavailability and limited clinical benefits. BPM31510, a novel formulation of CoQ10, was developed to overcome these delivery challenges, helping improve mitochondrial functioning. In preclinical studies using human cells with severe metabolic impairment, BPM31510 preserved cell viability, whereas cells treated with CoQ10 alone died within a week. BPM31510 has been granted a Rare Pediatric Disease Designation from the U.S. Food and Drug Administration for the treatment of primary CoQ10 deficiency.
“Advanced omics technology allowed us to pinpoint the exact cells in which CoQ10 is being delivered following treatment with BPM31510,” said Michael Kiebish, Ph.D., Vice President, Platform and Translational Sciences of BPGbio. “These data shows that BPM31510 crosses the blood-brain barrier—a major achievement—and delivers CoQ10 to the cerebellum, which may help address the ataxic symptoms common in primary CoQ10 deficiency. It also significantly boosts CoQ pools in the heart, kidney, and muscle which makes it a potential therapy for other mitochondrial diseases as well.”
“At BPGbio, we are redefining what’s possible in mitochondrial medicine,” said Niven R. Narain, Ph.D., President and CEO of BPGbio. “These compelling new data on BPM31510 reinforce our commitment to advancing the science of mitochondrial biology and delivering transformative therapies to patients with rare, life-altering diseases like primary CoQ10 deficiency. As we advance our clinical data on Primary CoQ10 Deficiency, we look forward to the best commercial and community partnerships to unleash the full potential of this therapy for patients and their families.”
Poster Presentation Details:
Title: Spatial and LC MS/MS Based Quinomics Reveals Novel Therapeutic Impact of BPM31510 For the Treatment of CoQ10 Deficiency Using the Coq4KI/KI Mouse Model
Date and Time: Monday, April 28 and Tuesday, April 29
